Losartan failed to reduce lung injury or improve clinical outcomes in patients hospitalized with COVID-19, researchers reported in JAMA Network Open.“Even though this particular drug was not effective for the treatment of COVID-19, repurposing inexpensive and relatively safe medications remains an important approach to contain health care costs,” Michael A. Puskarich, MD, MS,